The Road to Interoperability
The FDA has accepted TraceLink's blockchain and digital recall project into its DSCSA Pilot Program
Maryam Mahdi | | Quick Read
TraceLink has been approved to join the FDA’s Pilot Project Program, which aims to support drug supply stakeholders, including the FDA, in developing interoperable electronic systems capable of tracing Rx drugs through their distribution. Projects will begin in August 2019, and the FDA plans to publish a report based on the findings to help solve challenges associated with the current pharmaceutical supply chain and protect consumers against counterfeit medications.
TraceLink entered a submission focused on two workstreams: an interoperable blockchain network solution called Trace Histories, and digital recalls. Both are intended to bring together companies from across the pharmaceutical supply chain.
“We are interested in the power of blockchain because of its ability to provide secure, immutable methods of information sharing across the industry. The Trace Histories workstream will explore the validity of using blockchain technology in a revolutionary way, which enables participants to post and share necessary compliance information on the blockchain while simultaneously safeguarding confidential business information.” explains Paul Cianciolo, Senior Vice President, Business Management at Tracelink.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.